Considering the importance of IL-1β and IL-18 in obesity-associated NASH and, consequently, in HCC progression, their therapeutic exploration appears to be promising for the management of this lethal cancer. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.